Track topics on Twitter Track topics that are important to you
It offloaded the drugs to Charterhouse Capital Partner’s Cooper-Vemedia for €158 million, with the products ranging across dermatology, eye-care and antiseptics.
The products are considered to be non-core products for Sanofi, mainly selling in France and Italy.
Sanofi revealed that it would be divesting of the assets and the sites currently manufacturing them would remain in its hands.
Original Article: Sanofi looks to trim down with divestmentsNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...